Endo Tools Reports 1st U.S. Commercial Cases of the Endomina System

Endo Tools Reports 1st U.S. Commercial Cases of the Endomina System
Endomina System

Endo Tools Therapeutics (ETT), developers of advanced endoscopic medical devices, today announced first U.S. commercial cases of the endomina® system. The system is designed for endoscopic placement of suture(s) and approximation of soft tissue in the gastrointestinal tract. The first endomina procedures were performed by Dr. Chris Thompson and Dr. Pichamol Jirapinyo at Brigham and Women’s Hospital in Boston, MA.

“We are thrilled to be the first hospital in the U.S. to perform gastric procedures using the endomina system. The system offers a minimally invasive option with a large working space to approximate very large plications,” said Dr. Thompson. “I look forward to incorporating endomina into my daily practice, as I found it particularly easy to learn and use due to its unique design.”

The endomina system is comprised of a triangulation platform and suturing units (TAPES). It can be affixed to various tested standard endoscopes, providing a bendable therapeutic channel that can move independently. Physicians will be able to perform suturing like a laparoscopic intervention but through a natural orifice, the mouth. The endomina system is the only technology that can be assembled on the endoscope in the stomach for a greater working space and easy introduction of instruments into the esophagus.

“We are delighted the endomina system is now available to patients and physicians in the U.S. market,” said Alexandre Chau, chief executive officer, Endo Tools Therapeutics. “The successful completion of these first cases in the U.S. demonstrates potential for this technology to improve the lives of patients undergoing gastric surgery.”

The endomina system is CE marked and has received 510k clearance in the U.S. More than 500 procedures have already been performed with the company’s devices globally.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version